Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
Bortezomib is the first proteasome inhibitor to treat a variety of malignancies and is currently part of the standard of care regimen for the initial treatment of patients with newly diagnosed multiple myeloma. While bortezomib is generally well tolerated, it has been associated with various side ef...
Saved in:
Main Authors: | Joseph Han (Author), Shayan Owji (Author), Aneesh Agarwal (Author), Samir Kamat (Author), Yen Luu (Author), Adnan Mubasher (Author), George Niedt (Author), Chloe Ray (Author), Hearn Jay Cho (Author), Nicholas Gulati (Author), Angela Lamb (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cutaneous Drug Reaction Due to Bortezomib Characterized by Erythematous Reticular Plaques in a Patient With Multiple Myeloma
by: Emre Güven, et al.
Published: (2024) -
A case of lichenoid drug eruption associated with relugolix
by: Joseph Han, BS, et al.
Published: (2023) -
Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide
by: Mitsutoshi Satoh, et al.
Published: (2011) -
Skin lesions caused by bortezomib targeted therapy of multiple myeloma
by: Michał Sobjanek, et al.
Published: (2016) -
Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
by: Chen W, et al.
Published: (2016)